VEC Share Price

Open 140.10 Change Price %
High 140.60 1 Day 0.00 0.00
Low 137.95 1 Week -10.30 -6.87
Close 139.70 1 Month 2.50 1.82
Volume 1592293 1 Year -33.70 -19.43
52 Week High 200.10
52 Week Low 122.90
VEC Important Levels
Resistance 2 142.16
Resistance 1 141.14
Pivot 139.42
Support 1 138.26
Support 2 137.24
LON UK Most Active Stocks
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
HER 0.02 0.00%
HER 0.02 0.00%
LLOY 57.55 -0.07%
VOD 191.40 0.21%
VOD 191.40 0.21%
OTC 0.03 0.00%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
LDP 0.03 50.00%
LDP 0.03 50.00%
AMC 13.50 25.58%
AMC 13.50 25.58%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

Vectura Group PLC (LON: VEC)

VEC Technical Analysis 3
As on 2nd Dec 2016 VEC Share Price closed @ 139.70 and we RECOMMEND Sell for LONG-TERM with Stoploss of 154.90 & Sell for SHORT-TERM with Stoploss of 139.86 we also expect STOCK to react on Following IMPORTANT LEVELS.
VEC Target for December
1st Target up-side 156.92
2nd Target up-side 166.39
3rd Target up-side 175.86
1st Target down-side 129.88
2nd Target down-side 120.41
3rd Target down-side 110.94
VEC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.vectura.co.uk
VEC Address
VEC
One Prospect West
Chippenham, SN14 6FH
United Kingdom
Phone: 44 1249 667700
Fax: 44 1249 667701
Interactive Technical Analysis Chart Vectura Group PLC ( VEC LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vectura Group PLC
VEC Business Profile
Vectura Group plc develops pharmaceutical therapies for the treatment of bronchopulmonary diseases. Its products target various diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company offers ADVATE, a serum-free recombinant factor VIII for haemophilia A; Adept, a 4% icodextrin solution used during surgery to reduce post-surgical adhesions; Extraneal, a solution containing icodextrin for peritoneal dialysis; and Seebri Breezhaler, a long-acting muscarinic antagonist for the treatment of COPD, as well as Asmasal Clickhaler, Asmabec Clickhaler, and Meptin for the treatment of asthma. Its product pipeline comprises QVA149, a fixed-dose combination of indacaterol maleate and glycopyrronium bromide for the treatment of adult patients with COPD; VR315 and VR632 that are inhaled combination therapies for asthma and COPD; VR506, an inhaled corticosteriod for the treatment of asthma; VR496, an inhaled, locally acting treatment for symptoms of inflammatory respiratory disease; and VR040, an inhaled, systemically acting form of apomorphine hydrochloride for treating off episodes associated with advanced Parkinson's disease. The company also provides various drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to allow aerosolized drug particles to achieve high lung deposition with low-dose variability; GyroHaler and OmniHaler, which are multi-unit dose DPI devices designed to deliver locally acting drugs to the lungs; Clickhaler, a single-dose inhaler; and Duohaler, a dry powder inhaler. It has development collaborations and license agreements with Novartis AG, Sandoz, Baxter International Inc, GlaxoSmithKline, and Tianjin KingYork Group Company Limited. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.